ESMO临床实践指南转移性非小细胞肺癌的诊断治Word文件下载.docx

ESMO临床实践指南转移性非小细胞肺癌的诊断治Word文件下载.docx

《ESMO临床实践指南转移性非小细胞肺癌的诊断治Word文件下载.docx》由会员分享，可在线阅读，更多相关《ESMO临床实践指南转移性非小细胞肺癌的诊断治Word文件下载.docx（9页珍藏版）》请在冰豆网上搜索。

speakers0bureau:

AbbottDiagnostics,Roche,AstraZeneca,EliLilly,Pfizer.SPhasreported:

consultancy/honoraria:

Roche,EliLilly,AstraZeneca,Pfizer,BoehringerIngelheim,Bristol-MyersSquibb,MerckSerono,DaiichiSankyo,Tesaro.DDRhasdeclarednopotentialconflictsofinterest.references1.JemalA,BrayF,CenterMMetal.Globalcancerstatistics.CACancerJClin2011;

61:

69–90.2.FieldJK,OudkerkM,PedersenJH,DuffySW.Prospectsforpopulationscreeninganddiagnosisoflungcancer.Lancet2013;

382:

732–741.3.MalvezziM,BertuccioP,LeviFetal.Europeancancermortalitypredictionsfortheyear2012.AnnOncol2012;

23:

1044–1052.4.InternationalAgencyforResearchonCancer（IARC.http:

//www.iarc.fr/（23May2014,datelastaccessed.5.MalvezziM,BertuccioP,LeviFetal.Europeancancermortalitypredictionsfortheyear2013.AnnOncol2013;

24:

792–800.6.WakeleeHA,ChangET,GomezSLetal.Lungcancerincidenceinneversmokers.JClinOncol2007;

25:

472–478.7.EdwardsBK,BrownML,WingoPAetal.Annualreporttothenationonthestatusofcancer,1975–2002,featuringpopulation-basedtrendsincancertreatment.JNatlCancerInst2005;

97:

1407–1427.8.TohCK,GaoF,LimWTetal.Never-smokerswithlungcancer:

epidemiologicevidenceofadistinctdiseaseentity.JClinOncol2006;

2245–2251.9.TravisWD,BrambillaE,NoguchiMetal.InternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySociety:

internationalmultidisciplinaryclassificationoflungadenocarcinoma:

executivesummary.ProcAmThoracSoc2011;

8:

381–385.10.SequistLV,WaltmanBA,Dias-SantagataDetal.GenotypicandhistologicalevolutionoflungcancersacquiringresistancetoEGFRinhibitors.SciTranslMed2011;

3:

75ra26.11.KerrKM,BubendorfL,EdelmanMJetal.2ndESMOConsensusConferenceonLungCancer:

pathologyandmolecularbiomarkersfornon-small-celllungcancer.AnnOncol2014June17[epubaheadofprint],doi:

10.1093/annonc/mdu145.12.BesseB,AdjeiA,BaasPetal.2ndESMOConsensusConferenceonLungCancer:

non-small-celllungcancerfirst-line/secondandfurtherlinesoftreatmentinadvanceddisease.AnnOncol2014;

1475–1484.13.RekhtmanN,PaikPK,ArcilaMEetal.Clarifyingthespectrumofdriveroncogenemutationsinbiomarker-verifiedsquamouscarcinomaoflung:

lackofEGFR/KRASandpresenceofPIK3CA/AKT1mutations.ClinCancerRes2012;

18:

1167–1176.14.KwakEL,BangYJ,CamidgeDRetal.Anaplasticlymphomakinaseinhibitioninnon-small-celllungcancer.NEnglJMed2010;

363:

1693–1703.15.ShawAT,YeapBY,Mino-KenudsonMetal.Clinicalfeaturesandoutcomeofpatientswithnon-small-celllungcancerwhoharborEML4-ALK.JClinOncol2009;

27:

4247–4253.16.WuY,LiP,ZhangHetal.Diagnosticvalueoffluorine18fluorodeoxyglucosepositronemissiontomography/computedtomographyforthedetectionofmetastasesinnon-small-celllungcancerpatients.IntJCancer2013;

132:

E37–E47.17.EisenhauerEA,TherasseP,BogaertsJetal.Newresponseevaluationcriteriainsolidtumours:

revisedRECISTguideline（version1.1.EurJCancer2009;

45:

228–247.18.BaserS,ShannonVR,EapenGAetal.Smokingcessationafterdiagnosisoflungcancerisassociatedwithabeneficialeffectonperformancestatus.Chest2006;

130:

1784–1790.19.HughesAN,O’BrienME,PettyWJetal.OvercomingCYP1A1/1A2mediatedinductionofmetabolismbyescalatingerlotinibd